Two epitopes shared by Taenia crassiceps and Taenia solium confer protection against murine T. crassiceps cysticercosis along with a prominent T1 response.
Taenia crassiceps recombinant antigens KETc1 and KETc12 have been shown to induce high level of protection against experimental murine T. crassiceps cysticercosis, an experimental model successfully used to test candidate antigens for use in vaccination against porcine Taenia solium cysticercosis. Based on the deduced amino acid sequence, KETc1 and KETc12 were chemically synthesized in linear form. Immunization with KETc1 induced 66.7 to 100% protection against murine cysticercosis, and immunization with KETc12 induced 52.7 to 88.1% protection. The elicited immune response indicated that both peptides contain at least one B-cell epitope (as demonstrated by their ability to induce specific antibodies) and one T-cell epitope that strongly stimulated the proliferation of T cells primed with either the free peptide or total cysticercal T. crassiceps antigens. The high percentage of spleen cells expressing inflammatory cytokines points to the likelihood of a T1 response being involved in protection. The protective capacity of the peptides and their presence in all developmental stages of T. solium point to these two epitopes as strong candidates for inclusion in a polyepitopic synthetic vaccine against T. solium pig cysticercosis.
Toledo
A
A
Instituto de Investigaciones Biomédicas, Benemérita Universidad Autónoma de Puebla, Puebla, México.
Fragoso
G
G
Rosas
G
G
Hernández
M
M
Gevorkian
G
G
López-Casillas
F
F
Hernández
B
B
Acero
G
G
Huerta
M
M
Larralde
C
C
Sciutto
E
E
D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D000947:Antigens, Helminth / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use*; D003551:Cysticercosis / Q000276:immunology / Q000517:prevention & control*; D000939:Epitopes / Q000302:isolation & purification / Q000627:therapeutic use; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments / Q000627:therapeutic use; D013045:Species Specificity; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013621:Taenia / Q000276:immunology*; D014611:Vaccination; D014612:Vaccines / Q000627:therapeutic use*
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D000939:Epitopes; D010446:Peptide Fragments; D014612:Vaccines